SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1)
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro. ASH 2016. Poster
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model Oral Presentation
SL-401, a Novel IL-3R/CD123-Directed Agent Targets Stem-Like Cells in Multiple Myeloma
SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-Like Cells in Multiple Myeloma Poster
Results From Ongoing Phase 2 Registration Study of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Results From Ongoing Phase 2 Registration Study Of SL-401 In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2016. Abstract
Results From Phase 2 Registration Trial of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing
Results From Phase 2 Registration Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing. ASCO 2016. Abstract
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). ASH 2015. Poster
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo. ASH 2015. Poster
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. ASH 2015. Poster
A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism
A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-associated Mechanism. ASH 2015. Poster
SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) With Broad and Potent Anti-Cancer Activity.
SL-801, a novel, reversible inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with broad and potent anti-cancer activity. ASH 2015. Poster